Transforming Infection & Inflammation Care with Precision Nanomedicine

Pioneering next-generation therapies to combat infections, inflammation, and surgical complications — from Edmonton to the world.

VISION

Deliver innovative, site-specific therapies that improve patient outcomes, reduce systemic side effects, and lower the burden on healthcare systems.

At FeynMED Solutions, we are reimagining how localized infections and inflammatory conditions are treated. Based in Edmonton, Alberta, with a cutting-edge cGMP facility, we harness the power of precisely engineered nanocrystalline silver to develop targeted therapeutics and medical devices that address some of healthcare’s most stubborn challenges — all while helping to curb global antimicrobial resistance (AMR).

OUR TECHNOLOGY

Therapeutic Nanocrystalline Silver

This platform technology is used for the treatment of:

Wounds & Burns

Abdominal Adhesions

Urinary Tract Infections (UTIs)

Pulmonary diseases

Viral ocular infection

Antimicrobial Resistance

Nanocrystalline Silver

Our patented platform controls the atomic and structural properties of silver nanocrystals to achieve unparalleled antimicrobial and anti-inflammatory effects. Unlike conventional antibiotics or steroids, our nanocrystalline silver targets infections and inflammation locally, preserving healthy tissue and minimizing systemic exposure.

Triple-action: Potent bactericidal, antiviral, and anti-inflammatory activity.
Versatile: Tunable formulations for diverse tissues and delivery routes.
Scalable: Manufactured efficiently at our Edmonton cGMP facility for global distribution.

Our Focus: Wound & Burn Care

Our first market-ready product targets chronic and acute wounds, leveraging proven nanocrystalline silver technology to accelerate healing, reduce infections, and minimize hospital stays. We are currently exploring licensing opportunities to bring this innovation rapidly to market.

Our focus:
Abdominal Adhesion Prevention

Nearly 95% of patients undergoing abdominal surgery develop adhesions, which can lead to chronic pain, bowel obstructions, and costly reoperations. Our novel intraperitoneal nanosilver therapy is designed to prevent these adhesions, setting a new standard of care in surgical recovery.

Our Focus:
Pulmonary Infections

Hospital-acquired pneumonias and infections in COPD patients pose growing threats. Our inhaled nanosilver formulations deliver targeted therapy to the lungs, potentially reducing reliance on systemic antibiotics and improving respiratory outcomes.

Our Focus: Urinary Tract Infections (UTIs)

Recurrent and catheter-associated UTIs are a major quality-of-life and cost burden, particularly in long-term care. Our bladder instillation therapies aim to simultaneously treat infections and inflammation, preventing scarring and chronic complications.

Our focus:
Ocular Applications

Eye infections and inflammation can jeopardize vision and require intensive treatments. Our ophthalmic drops harness nanosilver’s triple-action properties to address these conditions more effectively and safely.

WHY FeynMED

FeynMED is built on a vision of transforming how localized infections and inflammatory conditions are treated

By focusing on both immediate market opportunities, like wound care, and large-scale unmet needs in surgical adhesion prevention, pulmonary infections, urinary tract infections, and ocular diseases, FeynMED is uniquely positioned to drive patient-centered innovation and deliver meaningful health and economic impact across Canada and around the world.

FeynMED In Numbers

200M+

POTENTIAL PATIENTS

CORE TEAM MEMBERS

MEDICAL APPLICATIONS